Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 12TCr 42Cr 37Cr 34Cr 32Cr 60Cr 4.01TCr 61Cr 411.1Cr 159.6Cr 1.98TCr 159.36Cr 155.8Cr 6.89TCr P/E 2026 *
10.7x
P/E 2027 * 9.17x
Enterprise Value 12TCr 42Cr 37Cr 34Cr 32Cr 60Cr 4.01TCr 61Cr 411.1Cr 159.6Cr 1.98TCr 159.36Cr 155.8Cr 6.89TCr EV / Sales 2026 *
1.71x
EV / Sales 2027 * 1.58x
Free-Float
16.89%
Yield 2026 *
5.01%
Yield 2027 * 5.62%
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
01/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
27/04 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
09/04 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
07/04 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
31/03 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
26/03 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
24/25/24 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
02/25/02 GlaxoSmithKline Pakistan Limited Declares Interim Cash Dividend for the Half Year Ended June 30, 2025 CI
26/25/26 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day+1.66%
1 week+3.07%
1 month+4.36%
3 months+17.57%
6 months-5.01%
Current year-5.01%
1 week 363
Extreme 363
373
1 month 344.01
Extreme 344.01
384.2
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Director of Finance/CFO - 01/06/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.66%+3.07%-5.24%+391.24% 42Cr
-2.48%+8.34%+53.87%+155.75% 1,09700Cr
-1.76%+6.23%+66.27%+53.44% 62TCr
-1.05%+7.19%+35.57%+86.77% 45TCr
+0.83%+4.18%+31.11%+23.88% 33TCr
-1.38%+3.75%+39.33%+25.04% 29TCr
+0.30%+2.56%+31.62%+40.64% 29TCr
-0.10%+2.23%-28.43%-42.77% 21TCr
+0.44%+4.35%+29.69%+63.10% 19TCr
+0.01%+1.03%+13.95%+63.93% 16TCr
Average -0.32%+5.25%+26.77%+86.10% 36.47TCr
Weighted average by Cap. -1.12%+7.04%+40.91%+77.70%

Financials

2026 *2027 *
Net sales 6.88TCr 25Cr 22Cr 20Cr 19Cr 35Cr 2.34TCr 36Cr 239.91Cr 93Cr 1.15TCr 93Cr 91Cr 4.02TCr 7.46TCr 27Cr 23Cr 22Cr 20Cr 38Cr 2.54TCr 39Cr 260.01Cr 100.94Cr 1.25TCr 100.79Cr 99Cr 4.36TCr
Net income 1.05TCr 3.77Cr 3.3Cr 3.05Cr 2.84Cr 5.36Cr 356.79Cr 5.45Cr 37Cr 14Cr 176.06Cr 14Cr 14Cr 613.37Cr 1.24TCr 4.47Cr 3.91Cr 3.61Cr 3.37Cr 6.34Cr 422.45Cr 6.46Cr 43Cr 17Cr 208.47Cr 17Cr 16Cr 726.25Cr
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
30/26/30 PKR 370.25 +1.66% 3,96,486
29/26/29 PKR 364.22 -0.73% 3,09,601
24/26/24 PKR 366.89 +2.14% 2,11,025
23/26/23 PKR 359.21 -1.10% 2,54,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
370.25PKR
Average target price
517.50PKR
Spread / Average Target
+39.77%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock